Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin crossover mechanistic renal oxygenation study in type 2 diabetes and matched healthy controls
NL-OMON55355Phase 4Not yet recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ertugliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Vrije University Medical Center. Primary endpoint: Renal cortical and medullary oxygenation. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON55355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55355.